Mazdutide
LY3305677 / IBI362
Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.
작용 메커니즘
Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Phase 3 research protocols use 4mg to 9mg biweekly subcutaneous injection.
연구 노트
Clinical Research Status
Mazdutide has completed multiple Phase 3 trials in China, with regulatory submission to China's NMPA anticipated or underway. The GLORY Phase 3 program demonstrated up to 14.4% body weight loss at 48 weeks in Chinese patients with obesity. Innovent holds rights for the Chinese market while Eli Lilly retains rights for other territories, though global development timelines remain less defined.
Key Published Findings
Phase 2/3 data showed dose-dependent weight loss with the 6mg and 9mg doses demonstrating the strongest efficacy. The glucagon receptor component is hypothesized to increase energy expenditure and promote hepatic lipid oxidation beyond what GLP-1 agonism alone achieves. HbA1c reductions of 1.5-2.0% have been observed in diabetic populations, suggesting robust dual metabolic benefit.
Safety Profile
Gastrointestinal adverse events remain the most common class effect, with nausea and diarrhea reported in 20-40% of patients during titration. The glucagon component raises theoretical concerns about hepatic glucose output, though hyperglycemia has not emerged as a significant finding in clinical data. Heart rate increases have been observed, consistent with GLP-1 agonist class effects, and long-term cardiovascular outcome data is not yet available.
Comparison to Related Compounds
Mazdutide shares the dual GLP-1/glucagon mechanism with survodutide (Boehringer Ingelheim) but has advanced further in regulatory timelines within China. Unlike tirzepatide which targets GIP/GLP-1, mazdutide's glucagon component is designed to boost energy expenditure rather than enhance incretin signaling. The weight loss magnitude appears intermediate between semaglutide monotherapy and the highest tirzepatide doses.
Community Observations
Mazdutide represents one of the most advanced obesity therapeutics developed primarily for the Asian market, where metabolic disease prevalence is rising rapidly. Researchers note the glucagon component may offer particular benefit for NAFLD/MASH given glucagon's role in hepatic fat metabolism. The compound's development trajectory illustrates the growing importance of the Chinese pharmaceutical market for peptide therapeutics.
반감기
~5-6 days
재조성
Bacteriostatic water (BAC)
보관
건조한 상태
Refrigerate 2-8C. Protect from light.
재조성된 상태
Refrigerate 2-8C. Use within 21 days.
미국 법적 상태
또는 알려진 이름으로
최신 연구
자주 묻는 질문
Mazdutide란 무엇인가요?
Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.
Mazdutide는 어떻게 작용하나요?
Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.
Mazdutide의 미국 규제 현황은 어떤가요?
Research chemical (not FDA-approved)
Mazdutide의 반감기는 얼마인가요?
~5-6 days
Mazdutide의 다른 이름은 무엇인가요?
LY3305677, IBI362
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기